Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Ribupatide in Renal Impairment
NCT07793929Phase 1Recruiting
- Sponsor
- Kailera Therapeutics
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribupatide in obesity, sponsored by Kailera Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at Day 35, Area Under Concentration Time Curve From Time Zero to Time of the Last Measurable Concentration at Day 35 and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
ribupatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07793929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793929.